SCHEMBL31093004

SCHEMBL31093004

C=C(CCN1CCCCCN1CCC(=C)c1ccccc1)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 2/20 0.49
SLC6A3 Q01959 2/20 0.49
ALDH1A1 P00352 4/20 0.47
KMT2A Q03164 3/20 0.47
GFER P55789 1/20 0.46
HPGD P15428 1/20 0.42
CHRNB2 P17787 1/20 0.41
CHRNB4 P30926 1/20 0.41
CHRNA3 P32297 1/20 0.41
CHRNA4 P43681 1/20 0.41
MAOA P21397 2/20 0.39
MAOB P27338 2/20 0.39
PSMB1 P20618 1/20 0.39
PSMB5 P28074 1/20 0.39
HTT P42858 1/20 0.39
SIGMAR1 Q99720 1/20 0.38
USP2 O75604 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31093103 0.90 SLC6A3 (0.45) SLC6A4SLC6A3ALDH1A1KMT2AGFER
SCHEMBL9779110 0.86 ALDH1A1 (0.65) SLC6A4SLC6A3ALDH1A1KMT2AGFER
SCHEMBL1903553 0.84 ALDH1A1 (0.62) SLC6A4SLC6A3ALDH1A1KMT2AGFER
SCHEMBL31093170 0.79 SLC6A4 (0.69) SLC6A4SLC6A3ALDH1A1KMT2AGFER
SCHEMBL31093052 0.78 SLC6A4 (0.43) SLC6A4SLC6A3ALDH1A1KMT2AGFER
SCHEMBL9779048 0.76 CHRNB2 (0.53) ALDH1A1KMT2AGFERHPGDCHRNB2
SCHEMBL31093121 0.74 SLC6A4 (0.62) SLC6A4SLC6A3ALDH1A1KMT2AGFER
SCHEMBL7990104 0.73 MAOA (0.56) SLC6A4SLC6A3ALDH1A1KMT2AHPGD
SCHEMBL5597945 0.73 CHRNB2 (0.50) SLC6A4SLC6A3ALDH1A1KMT2AGFER
SCHEMBL31092931 0.72 SLC6A4 (0.57) SLC6A4SLC6A3ALDH1A1KMT2AGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260035497-A1 AMINE CONTAINING COPOLYMERS VIA EMULSION POLYMERIZATION AND METHODS OF USE THEREOF INFINEUM INTERNATIONAL LIMITED (US) 2026-02-05 US claimed
US-20260035493-A1 AMINE CONTAINING COPOLYMERS VIA RADICAL POLYMERIZATION AND METHODS OF USE THEREOF INFINEUM INTERNATIONAL LIMITED (US) 2026-02-05 US claimed
US-20250250379-A1 AMINE CONTAINING POLYMER COMPOSITIONS AND USES THEREOF INFINEUM INTERNATIONAL LIMITED (US) 2025-08-07 US claimed
EP-4596661-A1 AMINE CONTAINING POLYMER COMPOSITIONS AND USES THEREOF Infineum International Limited (GB) 2025-08-06 EP claimed
US-20240287009-A1 AMINE-FUNCTIONAL MONOMERS AND METHODS OF MAKING SAME INFINEUM INTERNATIONAL LIMITED (GB) 2024-08-29 US claimed
EP-4410772-A2 AMINE-FUNCTIONAL MONOMERS AND METHODS OF MAKING SAME Infineum International Limited (GB) 2024-08-07 EP claimed
CN-118440229-A Amine functional monomers and methods of making the same 英菲诺姆国际有限公司 2024-08-06 CN claimed
US-20260035495-A1 FUNCTIONAL COPOLYMERS AND METHODS OF PREPARATION THEREOF Kraton Corporation (US) 2026-02-05 US disclosed
US-20260035497-A1 AMINE CONTAINING COPOLYMERS VIA EMULSION POLYMERIZATION AND METHODS OF USE THEREOF INFINEUM INTERNATIONAL LIMITED (US) 2026-02-05 US disclosed
US-20260035493-A1 AMINE CONTAINING COPOLYMERS VIA RADICAL POLYMERIZATION AND METHODS OF USE THEREOF INFINEUM INTERNATIONAL LIMITED (US) 2026-02-05 US disclosed
US-20250250379-A1 AMINE CONTAINING POLYMER COMPOSITIONS AND USES THEREOF INFINEUM INTERNATIONAL LIMITED (US) 2025-08-07 US disclosed
EP-4596661-A1 AMINE CONTAINING POLYMER COMPOSITIONS AND USES THEREOF Infineum International Limited (GB) 2025-08-06 EP disclosed
US-20240287009-A1 AMINE-FUNCTIONAL MONOMERS AND METHODS OF MAKING SAME INFINEUM INTERNATIONAL LIMITED (GB) 2024-08-29 US disclosed
EP-4410772-A2 AMINE-FUNCTIONAL MONOMERS AND METHODS OF MAKING SAME Infineum International Limited (GB) 2024-08-07 EP disclosed
CN-118440229-A Amine functional monomers and methods of making the same 英菲诺姆国际有限公司 2024-08-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035495-A1 FUNCTIONAL COPOLYMERS AND METHODS OF PREPARATION THEREOF VCL, FGB, CDH1 SLC6A4 4190/4885SLC6A3 3824/4885ALDH1A1 303/4885
US-20260035493-A1 AMINE CONTAINING COPOLYMERS VIA RADICAL POLYMERIZATION AND METHODS OF USE THEREOF CBS, SELP, RAD51 SLC6A4 967/4885SLC6A3 1604/4885ALDH1A1 813/4885
US-20240287009-A1 AMINE-FUNCTIONAL MONOMERS AND METHODS OF MAKING SAME AMD1, HNMT, MAT1A SLC6A4 2274/4885SLC6A3 2219/4885ALDH1A1 317/4885
US-20260035497-A1 AMINE CONTAINING COPOLYMERS VIA EMULSION POLYMERIZATION AND METHODS OF USE THEREOF DEGS1, SGMS1, PHOSPHO1 SLC6A4 2459/4885SLC6A3 3038/4885ALDH1A1 2406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.